A new draft of House legislation that creates significant new regulatory leeway for drug and device companies includes more funding for the National Institutes of Health, representing a compromise with Democrats who withdrew support for the bill. READ MORE
|
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Thursday, April 30, 2015
New draft of medical innovation bill boosts NIH funding
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment